Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Remegen

company

About

Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.

  • 11 - 50

Details

Last Funding Type
Private Equity(PE)
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$100M
Remegen has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Mar 17, 2020 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 17, 2020 Private Equity(PE) $100M 1 Lilly Asia Ventures Detail
Dec 7, 2019 Private Equity(PE) 2 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Remegen is funded by 3 investors. Lilly Asia Ventures and Huatai Health Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Yes Private Equity(PE)
Huatai Health Fund Private Equity(PE)
Mingxin China Growth Fund Private Equity(PE)